CEL-SCI Corp Offering - What You Need to Know

Thinking about investing in CEL-SCI Corp (CVM)? Before you put your money on the line, let’s break down what this company does, why they are raising money, and the risks involved.

Note: This guide helps you understand the basics. Always do your own research or talk to a financial advisor before investing.

1. What does this company do?

CEL-SCI is a biotech company developing treatments that use the body’s immune system to fight cancer. Their main project is Multikine, an experimental immunotherapy drug.

Most treatments happen after surgery. Multikine is different; it is designed to be given before surgery to stimulate the immune system while the tumor is still present. The company is testing this in patients with head and neck cancer. They are specifically targeting patients who do not respond well to current drugs like Keytruda. By focusing on this group, CEL-SCI hopes to fill a gap in current cancer care.

2. How do they make money?

The short answer is: they don’t. CEL-SCI has no products on the market and generates no sales revenue.

The company’s "growth" isn't measured by profit or sales. Instead, it is measured by how far they move their drug through the FDA approval process. Because they have no income, they have lost money every year since they started. They rely entirely on outside cash—like this stock offering—to pay for expensive research and clinical trials.

3. What is this new offering about?

CEL-SCI wants to raise about $6.5 million by selling stock at $1.20 per share.

• It’s a "Best Efforts" deal: The agent selling these shares does not have to sell a specific amount. If they don't find enough buyers, the company will receive less than $6.5 million, which could hurt their ability to operate.
• Management has "Broad Discretion": The company hasn't set a specific, detailed plan for how they will spend this money. They can use it for general costs, research, or trials. This gives management flexibility, but it means you don't know exactly how your money will be used.
• No Dividends: The company has never paid a dividend and does not plan to pay one in the future. They intend to keep all cash to fund their business.

4. What are the main risks?

Biotech is high-risk. Beyond the uncertainty of clinical trials, consider these red flags:

• "Going Concern" Warning: Auditors have expressed "substantial doubt" about the company’s ability to stay in business. They need more cash soon just to keep the lights on.
• Internal Control Issues: The company found "material weaknesses" in its accounting systems. This means there is a risk that their financial reports could contain errors.
• Dilution: Because the company constantly needs cash, they frequently issue new shares. This creates more shares, which reduces your ownership percentage and the value of your current stake.
• Legal Roadblocks: You may be limited in where you can sue the company. Their rules require most legal actions to take place in Delaware courts.
• Tax Complexity: If you live outside the U.S., you may face complex tax reporting and withholding rules on your shares.

5. Final Thought

Investing here is like betting on a race that hasn't started yet. The company is struggling financially and has admitted to weaknesses in its reporting. If Multikine is approved, it could be a major success. However, if trials fail or they run out of cash, you could lose your entire investment.

Before you buy: Ask yourself if you are comfortable with the "going concern" risk—the possibility that the company may not have enough cash to reach its goals. If you aren't prepared for the high likelihood of volatility and potential loss, this may not be the right investment for your portfolio.